Primary vs. pre-emptive anti-seizure medication prophylaxis in anti-CD19 CAR T-cell therapy
Umberto Pensato(Unknown), Stéfania Bramanti(Istituti di Ricovero e Cura a Carattere Scientifico), Maria Guarino(Fondazione Humanitas per la Ricerca), Federica Pondrelli(Istituto delle Scienze Neurologiche di Bologna), Chiara De Philippis(IRCCS Humanitas Research Hospital), Laura Straffi(IRCCS Humanitas Research Hospital), Gian Maria Asioli(Istituto delle Scienze Neurologiche di Bologna), Daniele Mannina(Humanitas University), Enrico Maffini(Istituto di Ematologia di Bologna), Beatrice Casadei(Istituto di Ematologia di Bologna), Francesca Bonifazi(University of Bologna), Pier Luigi Zinzani(Istituto di Ematologia di Bologna), Alessandra Crespi(IRCCS Humanitas Research Hospital), Alessandro Buizza(Istituti di Ricovero e Cura a Carattere Scientifico), Simona Marcheselli(Metropolitan Hospital)
Cited by 7
Related Papers
PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma
|New England Journal of Medicine|2014|1.1k
Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial
|The Lancet|2018|733
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
|The Lancet|2017|580
ALK+ lymphoma: clinico-pathological findings and outcome.
|PubMed|1999|569
Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial
|Nature Medicine|2021|523